International care models for chronic kidney disease: Methods and economics - United States

Blood Purification

Volumn 22, Issue 1, 2004, Pages 13-20

  Crooks, Peter ^a,b,c  

^a KAISER PERMANENTE   (United States)

^b Rockville Center   (United States)

^c NONE   (United States)

Author keywords

Care models; Chronic kidney disease; Economics; Renal disease; United States

Indexed keywords

ADULT; ASSOCIATION; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; MEDICAL INFORMATION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; UNITED STATES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE MANAGEMENT; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE, INTEGRATED; DRUG UTILIZATION; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE COVERAGE; INTERNATIONALITY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MEDICARE; MODELS, THEORETICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 0942278983     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074919     Document Type: Review

References (20)

1. Halvorson G, Isham G: Epidemic of Care. San Francisco, Jossey-Bass, 2003.
2. K/DOQI Clinical Practice Guidelines on Chronic Kidney Disease Work Group and Evidence Review Team: Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S50.
3. Rutkowski M, Mann W, Araki D, Wong G, Derose S, Ledezma M, Mihara N, Yeoh H, Crooks P: Chronic kidney disease staging in a large health maintenance organization: Refinement of K/DOQI staging and initial results. J Am Soc Nephrol 2002;13:463A.
4. Nissenson AR, Pereira BJ, Collins AJ, Steinberg EP: Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis 2001;37:1177-1183.
5. Collins AJ: Impact of congestive heart failure and other cardiac disease on patient outcomes. Kidney Int 2002;62:S3-S7.
6. Gibertson DT, Li S, Murray A, Herzog C, Collins A: The competing risks of death vs. ESRD in Medicare beneficiaries 65+ with chronic kidney disease. J Am Soc Nephrol 2002;13:439A.
7. Keith D, Nichols G, Gullion C, Brown J, Smith D: Mortality of chronic kidney disease (CKD) in a large HMO population. J Am Soc Nephrol 2002;13:620A.
8. London R, Solis A, Goldberg GA, Wade S, Ryu S: Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 2002;40:539-548.
9. Amedia CA: Managing chronic kidney disease. Managed Care 2003, pp 8-12.
10. Smith D, Gullion C, Nichols G, Keith D, Brown J: Costs of chronic kidney disease (CKD) in a large HMO population. J Am Soc Nephrol 2002;13:618A-619A.
11. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP: Opportunities for improving the care of patients with chronic renal insufficiency: Current practice patterns. J Am Soc Nephrol 2001;12:1713-1720.
12. Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, Owen W Jr: Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol 2002;55:711-716.
13. Stack AG: Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis 2003;41:310-318.
14. Bolton WK, Kliger AS: Chronic renal insufficiency: Current understandings and their implications. Am J Kidney Dis 2000;26:S4-S12.
15. Trivedi H, Pang M, Campbell A, Saab P: Slowing the progression of chronic renal failure: Economic benefits and patients' perspectives. Am J Kidney Dis 2002;39:721-729.
16. McLaughlin K, Manns B, Culleton B, Donaldson C, Taub K: An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am J Kidney Dis 2001;38:1122-1128.
17. Schadlich PK, Brecht JG, Brunetti M, Pagano E, Rangoonwala B, Huppertz E: Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: Economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 2001;19:497-512.
18. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S: To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 2000;162:195-198.
19. Yeoh H, Tiquia H, Abcar A, Rasgon S, Idroos M, Daneshvar S: Impact of predialysis care on clinical outcomes. Hemodialysis Int, in press.
20. Nissenson A: Disease management improves outcomes in patients with CKD: Nephrol News Issues 2003;17:15-19.